Definium Therapeutics US Patent US12611399B2 Psychedelic Movement Disorders
Summary
Definium Therapeutics US, Inc. has been granted US Patent 12611399B2 for a method of treating movement disorders using psychedelic compounds. The patent, with inventors Robert Barrow and Daniel R. Karlin, was filed on May 1, 2022, and contains 7 claims. The invention falls under CPC classification A61P 25/14 and covers administering an effective amount of a psychedelic to an individual having a movement disorder.
“A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
US Patent 12611399B2 has been granted to Definium Therapeutics US, Inc., covering a method of treating movement disorders by administering an effective amount of a psychedelic compound. The patent names Robert Barrow and Daniel R. Karlin as inventors and includes 7 claims under CPC classification A61P 25/14.
Parties developing psychedelic-based therapeutics for movement disorders should review this patent portfolio to assess potential licensing requirements or design-around considerations for their own compounds. Competitors in the pharmaceutical and biotech sectors working in this therapeutic area may face freedom-to-operate challenges.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Movement disorders
Grant US12611399B2 Kind: B2 Apr 28, 2026
Assignee
Definium Therapeutics US, Inc.
Inventors
Robert Barrow, Daniel R. Karlin
Abstract
A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.
CPC Classifications
A61P 25/14
Filing Date
2022-05-01
Application No.
17734102
Claims
7
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.